- £156.99bn
- £175.58bn
- $54.07bn
- 86
- 17
- 75
- 64
RCS - OMP - OMP Positioned Highest for Ability to Execute
AnnouncementREG - AstraZeneca PLC - Result of AGM
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for AEGEAN
AnnouncementREG - AstraZeneca PLC - Enhertu approved in EU in post-ET breast cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in the US for bladder cancer
AnnouncementREG - AstraZeneca PLC - Calquence recommended for EU approval in 1L MCL
AnnouncementREG - AstraZeneca PLC - AZN invests $2.5bn in Beijing R&D & manufacturing
AnnouncementREG - AstraZeneca PLC - AstraZeneca to acquire EsoBiotec
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for limited-stage SCLC
AnnouncementREG - AstraZeneca PLC - Eneboparatide Phase III trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementREG - AstraZeneca PLC - Imfinzi improved EFS in early-stage gastric cancer
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi recommended for EU approval for AEGEAN
Announcement